Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.42 |
| ▸ | ITGAL | P20701 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | ADK | P55263 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31492457 | 0.77 | AHR (0.60) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL398827 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL3876150 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL443938 | 0.73 | AHR (1.00) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL129649 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL317549 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL445281 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL276716 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL20159135 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR | |
| SCHEMBL446638 | 0.73 | AHR (0.56) | AHRKEAP1PDPK1NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| US-20250382646-A1 | ENGINEERED ENZYMES AND METHODS FOR THE SYNTHESIS OF DIVERSE TYROSINE ANALOGS | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-12-18 | — | — | US | disclosed |
| US-12421534-B2 | Engineered enzymes and method for the synthesis of diverse tyrosine analogs | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240417764-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY | 2024-12-19 | — | — | US | disclosed |
| EP-4426676-A2 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240175002-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2024-05-30 | — | — | US | disclosed |
| CN-111989321-B | KRAS G12C inhibitors | 米拉蒂治疗股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| US-20240101553-A1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2023081837-A9 | METHODS FOR THE PRODUCTION OF TRYPTOPHANS, TRYPTAMINES, INTERMEDIATES, SIDE PRODUCTS AND DERIVATIVES | MIAMI UNIVERSITY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024026129-A2 | TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | ENSEM THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| US-7585981-B2 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | MITSUBISHI RAYON CO., LTD. (JP) | 2009-09-08 | — | — | US | disclosed |
| EP-1327632-B1 | METHOD FOR PRODUCING TRIMER OF INDOLE DERIVATIVE, AND TRIMER OF INDOLE DERIVATIVE AND LAMINATED STRUCTURE THEREOF | MITSUBISHI RAYON CO (JP) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008110690-A2 | NOVEL INDOLE DERIVATIVES, METHODS FOR PREPARING SAME, AND USE THEREOF PARTICULARLY AS ANTIBACTERIAL AGENTS | UNIVERSITE JOSEPH FOURIER (FR) | 2008-09-18 | — | — | WO | disclosed |
| CN-100334088-C | Diaminopyrroloquinazoline compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE CO LTD (CH) | 2007-08-29 | — | — | CN | disclosed |
| US-7115751-B2 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | MITSUBISHI RAYON CO., LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20060211793-A1 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | MITSUBISHI RAYONE CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| CN-1791604-A | Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors | HOFFMANN LA ROCHE (CH) | 2006-06-21 | — | — | CN | disclosed |
| US-20060052509-A1 | Composition containing carbon nanotubes having coating thereof and process for producing them | MITSUBISHI RAYON CO., LTD. (JP) | 2006-03-09 | — | — | US | disclosed |
| US-20040019097-A1 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1327632-A1 | METHOD FOR PRODUCING TRIMER OF INDOLE DERIVATIVE, AND TRIMER OF INDOLE DERIVATIVE AND LAMINATED STRUCTURE THEREOF | Mitsubishi Rayon Co., Ltd. (JP) | 2003-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211793-A1 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | IDO1, IDO2, INMT | AHR 60/4885KEAP1 898/4885PDPK1 2364/4885 |
| US-20040019097-A1 | Method for producing trimer of indole derivative, and trimer of indole derivative and laminated structure thereof | IDO1, IDO2, INMT | AHR 51/4885KEAP1 1140/4885PDPK1 1952/4885 |
| US-20240101553-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | AHR 2218/4885KEAP1 182/4885PDPK1 459/4885 |
| US-20240175002-A1 | ENGINEERED SYNTHASE FOR PRODUCTION OF TRYPTOPHAN DERIVATIVES AND INTRANSIGENT SUBSTRATES | WARS1, TPH1, TPH2 | AHR 744/4885KEAP1 4355/4885PDPK1 1634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.